Abcam, ab213860, Mouse DLL4 ELISA Kit

Size: 1 x 96Tests
Mouse DLL4 ELISA Kit is a Sandwich (quantitative) ELISA for the measurement of Mouse DLL4 in Mouse in Cell/Tissue Extracts, Cell Culture Media, Biofluids samples.
Key facts
Detection method:Colorimetric,
Sample types:Cell Lysate, Cell culture supernatant, EDTA Plasma, Heparin Plasma, Serum,
Reacts with:Mouse,
Assay type:Sandwich (quantitative),
Sensitivity:< 10 pg/mL,
Range:15.6 - 1000 pg/mL,
Assay time:3h 30m,
Assay Platform:Pre-coated microplate (12 x 8 well strips)

Product details:
The Mouse DLL4 Enzyme-Linked Immunosorbent Assay (ELISA) kit (ab213860) is designed for the quantitative detection of Mouse DLL4 in cell culture supernatants, cell lysates, serum and plasma (heparin, EDTA).
The ELISA kit is based on standard sandwich enzyme-linked immunosorbent assay technology. A monoclonal antibody from rat specific for DLL4 has been pre-coated onto 96-well plates. Standards (Expression system for standard: NSO; Immunogen sequence: S28-P525) and test samples are added to the wells, a biotinylated detection polyclonal antibody from goat specific for DLL4 is added subsequently and then followed by washing with PBS or TBS buffer. Avidin-Biotin-Peroxidase Complex was added and unbound conjugates were washed away with PBS or TBS buffer. HRP substrate TMB was used to visualize HRP enzymatic reaction. TMB was catalyzed by HRP to produce a blue color product that changed into yellow after adding acidic stop solution. The density of yellow is proportional to the Mouse DLL4 amount of sample captured in plate.
Delta like ligand 4 is a protein that in humans is encoded by the DLL4 gene. It is mapped to 15q15.1. This gene is a homolog of the Drosophila delta gene. DLL4 is a transmembrane ligand for Notch receptors that shows restricted expression to endothelial cells (ECs), in particular to arteries and capillaries, and is involved in vascular development, and it also appeared to be a major trigger of Notch receptor activities previously implicated in arterial and vascular development. Mouse DLL4 could activate mouse Notch1 and mouse Notch4. DLL4 acts as a negative regulator of tumor angiogenesis, its blockade results in the striking uncoupling of tumor growth from vessel density, presenting a novel therapeutic approach even for tumors resistant to anti-VEGF therapies. In addition to it, this gene also plays an important role in promoting Th17 effector activity during mycobacterial challenge.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
DLL4 also known as Delta-like ligand 4 is a member of the Delta/Serrate/Lag-2 family. This target is a single-pass type I membrane protein with a molecular weight of approximately 65 kDa. It features prominently in the vascular endothelium where it impacts angiogenic activity. DLL4 acts as a ligand for Notch receptors initiating a signaling cascade important to cell fate decisions. DLL4 expression occurs mainly on the arterial endothelium and the tumor vasculature highlighting its significance in angiogenesis.
Biological function summary
DLL4 engages in precise regulation of angiogenesis and vascular development. It participates in the Notch signaling pathway playing an integral role in controlling endothelial cell proliferation differentiation and migration. DLL4 does not operate in isolation; instead it functions as part of the Notch receptor-ligand complex. This relationship effectively regulates the sprouting of new blood vessels ensuring proper vascular patterning and functional blood supply.
Pathways
DLL4 links directly to the Notch signaling and VEGF (vascular endothelial growth factor) pathways both of which play critical roles in vascular development and homeostasis. Through the Notch pathway DLL4 interacts with Notch1 and Notch4 receptors facilitating communication that inhibits endothelial cell proliferation distinguishing it from other pro-angiogenic factors. Its relationship with the VEGF pathway allows DLL4 to modulate angiogenic processes balancing vessel sprouting by opposing excessive VEGF-induced activities.
Aberrations of DLL4 influence cancer and cardiovascular diseases. Overexpression and dysregulation of DLL4 have been observed in various cancers where it contributes to tumor angiogenesis promoting the growth and spread of cancer cells. In cardiovascular disorders dysfunctional DLL4 signaling impacts vascular development which can lead to fatal arteriovenous malformations. In these conditions DLL4 interacts with proteins like Notch1 and VEGF underlining its critical involvement in pathological angiogenesis and vessel formation.